AstraZeneca(AZN) - 2023 Q4 - Earnings Call Presentation

Financial Highlights - Total Revenue for FY 2023 reached $45811 million, a 6% increase at CER[26] - Product Sales Gross Margin for FY 2023 was 811%, a +10 percentage points increase[26] - Operating profit for FY 2023 increased by >2x to $8193 million[26] - Core EPS for FY 2023 increased by 15% to $726[28] - Total Revenue from Oncology in FY 2023 was $184 billion, a 21% increase[40] - Total Revenue from Rare Disease in FY 2023 was $78 billion, a 12% increase[71] Growth Drivers and Future Outlook - Total Revenue ex COVID-19 increased by low teens %, specifically +15%[12] - BioPharmaceuticals CVRM FY 2023 revenue reached $106 billion, a growth of 18%[52] - BioPharmaceuticals R&I FY 2023 revenue reached $64 billion, a growth of 10%[52] - The company anticipates a low double-digit to low-teens percentage increase in both Total Revenue and Core EPS for 2024[32]